China Cord Blood (CO) Reports In-Line Q4 EPS

China Cord Blood (NYSE: CO) reported Q4 EPS of $0.03, in-line with the analyst estimate of $0.03. Revenue for the quarter came in at $24.3 million versus the consensus estimate of $25.87 million.

For earnings history and earnings-related data on China Cord Blood (CO) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Dare Bioscience (DARE) Tops Q2 EPS by 11c
• zSpace, Inc. (ZSPC) Reports Q2 results